<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04132648</url>
  </required_header>
  <id_info>
    <org_study_id>201907819</org_study_id>
    <nct_id>NCT04132648</nct_id>
  </id_info>
  <brief_title>Curcumin and Exercise in Chronic Kidney Disease</brief_title>
  <official_title>Vasoconstrictor Responsiveness in Contracting Muscle of CKD: Influence of Acute Curcumin Supplementation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicholas Kruse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic kidney disease (CKD) is associated with a pro-oxidative and pro-inflammatory state,&#xD;
      and this is thought to contribute to a decrease in vascular function leading to greater&#xD;
      cardiovascular disease (CVD) risk. Curcumin supplementation has been shown to reduce&#xD;
      oxidative stress and improve endothelial function at rest in healthy older humans, although&#xD;
      the magnitude of this effect remains unknown during exercise in CKD. The primary aim of this&#xD;
      proposal is to determine whether exercising blood flow and vasoconstrictor responsiveness are&#xD;
      improved as a result of acute oral supplementation with curcumin in patients with CKD. We&#xD;
      hypothesize that: 1) acute curcumin supplementation will increase steady state exercise blood&#xD;
      flow, and 2) reduce vasoconstriction induced by an acute sympathetic stimulus (cold pressor&#xD;
      test) CKD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Active muscles require an optimal amount of local blood flow to meet the functional and&#xD;
      metabolic demand of the exercising muscle. It is well known that maximal aerobic work&#xD;
      capacity and exercise tolerance are reduced in CKD, contributing to functional impairment and&#xD;
      loss of independence. A multitude of factors may be responsible for this outcome including&#xD;
      reduced blood flow to active muscle beds brought on by greater levels of oxidative stress in&#xD;
      CKD. Aging and some individuals with disease (coronary artery disease, hypertension,&#xD;
      diabetes) exhibit elevated resting sympathetic nerve activity (SNA), leading to greater&#xD;
      vasoconstriction and pressor responses during exercise. However, the magnitude of this effect&#xD;
      remains unknown in CKD. Importantly, there are a lack of interventions aimed at improving&#xD;
      blood flow and reduce sympathetic mediated vasoconstriction in patients with CKD.&#xD;
&#xD;
      Recent evidence in aging humans suggest that curcumin supplementation improves vascular&#xD;
      function by reducing oxidative stress. However, it remains unknown whether acute curcumin&#xD;
      supplementation can be regarded as an effective therapeutic strategy aimed at modulating&#xD;
      exercise vasodilation and sympathetic mediated vasoconstriction in CKD. Understanding the&#xD;
      mechanisms that impair vascular function within exercising muscle is important when&#xD;
      understanding implications for systemic blood pressure regulation, cardiovascular disease and&#xD;
      functional work capacity in CKD. Therefore, identifying a low cost, non-pharmaceutical&#xD;
      intervention and its potential impact on improving vascular function in CKD is a priority in&#xD;
      preventative cardiovascular disease medicine.&#xD;
&#xD;
      The present proposal aims to examine the effect of sympathetic vasoconstriction on the&#xD;
      differential changes in exercising blood flow in response to acute oral supplementation with&#xD;
      curcumin in patients with CKD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized Double-Blind Placebo-Controlled Crossover Clinical Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Patient, providers, and the investigative team will all be blinded to the randomization.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>%change forearm vascular condutance (FVC)</measure>
    <time_frame>2 hours</time_frame>
    <description>Percentage reduction in FVC in response to acute sympathetic stimulus (cold pressor test; CPT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>forearm blood flow (FBF)</measure>
    <time_frame>2 hours</time_frame>
    <description>steady state FBF during forearm hand-grip exercise and CPT</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Blood Pressure</condition>
  <condition>Hyperemia</condition>
  <condition>Vasoconstriction</condition>
  <arm_group>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive curcumin (Longvida) 2000 mg one time prior to exercise trials</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive placebo pill identical in appearance and taste to the supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <description>Oral supplement one time at 2,000 mg</description>
    <arm_group_label>Curcumin</arm_group_label>
    <other_name>Longvida</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral supplement one time at 2,000 mg</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for CKD subjects:&#xD;
&#xD;
        Age 45-80 years old CKD stage III and IV (estimated glomerular filtration rate: 15-60&#xD;
        mL/min/1.73m2) BMI &lt;40 kg/m2-1 Able to give informed consent&#xD;
&#xD;
        Exclusion Criteria for CKD subjects will include answering yes to the following questions:&#xD;
&#xD;
          -  Active participation in another study?&#xD;
&#xD;
          -  Dialysis?&#xD;
&#xD;
          -  End stage renal disease or kidney failure?&#xD;
&#xD;
          -  Kidney transplant?&#xD;
&#xD;
          -  Sever liver disease or transplant?&#xD;
&#xD;
          -  Diabetes?&#xD;
&#xD;
          -  Angina (i.e., chest discomfort/pain/pressure upon exertion)&#xD;
&#xD;
          -  Severe congestive heart failure?&#xD;
&#xD;
          -  Pacemaker/defibrillator?&#xD;
&#xD;
          -  Heart arrhythmia (i.e. Atrial fibrillation/flutter)?&#xD;
&#xD;
          -  Pregnant, breastfeeding, or unwilling to use adequate birth control?&#xD;
&#xD;
          -  Active infection or antibiotic therapy?&#xD;
&#xD;
          -  Immunosuppressive therapy within the last 3 months?&#xD;
&#xD;
          -  History of stroke?&#xD;
&#xD;
          -  Have you had a heart attack in the last 3 months?&#xD;
&#xD;
          -  Have you taken curcumin in last 3 months?&#xD;
&#xD;
          -  Current use of Hormone Replacement Therapy (if female)?&#xD;
&#xD;
          -  Current smoker?&#xD;
&#xD;
          -  Anemic (Hemoglobin count &lt;9)?&#xD;
&#xD;
        Inclusion Criteria for healthy middle-age and older subjects:&#xD;
&#xD;
        Age 45-80 years old BMI &lt;40 kg/m2 1 Able to give informed consent&#xD;
&#xD;
        Exclusion Criteria for health older subjects will include answering yes to the following&#xD;
        questions:&#xD;
&#xD;
          -  Chronic kidney disease?&#xD;
&#xD;
          -  Hypertension?&#xD;
&#xD;
          -  Asthma?&#xD;
&#xD;
          -  Heart disease?&#xD;
&#xD;
          -  Clinical depression?&#xD;
&#xD;
          -  Autonomic disorders?&#xD;
&#xD;
          -  Sleep apnea?&#xD;
&#xD;
          -  Sever liver disease or transplant?&#xD;
&#xD;
          -  Diabetes?&#xD;
&#xD;
          -  Heart attack?&#xD;
&#xD;
          -  Angina (i.e., chest discomfort/pain/pressure upon exertion)&#xD;
&#xD;
          -  Severe systolic or congestive heart failure?&#xD;
&#xD;
          -  Heart angioplasty/stent or bypass surgery?&#xD;
&#xD;
          -  Heart valve surgery/replacement or valve disease?&#xD;
&#xD;
          -  Pacemaker/defibrillator?&#xD;
&#xD;
          -  Heart arrhythmia (i.e. Atrial fibrillation/flutter)?&#xD;
&#xD;
          -  Pregnant, breastfeeding, or unwilling to use adequate birth control?&#xD;
&#xD;
          -  Active infection or antibiotic therapy?&#xD;
&#xD;
          -  Immunosuppressive therapy within the last 3 months?&#xD;
&#xD;
          -  Have you taken curcumin in last 3 months?&#xD;
&#xD;
          -  Current use of Hormone Replacement Therapy (if female)?&#xD;
&#xD;
          -  Current smoker?&#xD;
&#xD;
          -  Anemic (Hemoglobin count &lt;9)?&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicholas Kruse, Ph.D.</last_name>
    <phone>4199662797</phone>
    <email>nicholas-kruse-1@uiowa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diana Jala, M.D.</last_name>
    <phone>7204254154</phone>
    <email>diana-jalal@uiowa.edu</email>
  </overall_contact_backup>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 17, 2019</study_first_submitted>
  <study_first_submitted_qc>October 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2019</study_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Nicholas Kruse</investigator_full_name>
    <investigator_title>Postdoctoral Researcher</investigator_title>
  </responsible_party>
  <keyword>CKD</keyword>
  <keyword>Exercise</keyword>
  <keyword>Vasoconstrictor Responsiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hyperemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

